Several clinical trials are currently investigating the efficacy and safety of these agents, including compounds such as BH3 mimetics, BCL-2 protein inhibition, Smac mimetics, and CD95 agonists, in diverse cancer types, with encouraging preclinical outcomes demonstrating their potential as novel therapeutic interventions [70–72]. This evidence concerns the gene BCL2 and cancer.